11 results on '"de Gruijl, Tanja D."'
Search Results
2. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
- Author
-
Olson, Robert, Mathews, Lindsay, Liu, Mitchell, Schellenberg, Devin, Mou, Benjamin, Berrang, Tanya, Harrow, Stephen, Correa, Rohann J. M., Bhat, Vasudeva, Pai, Howard, Mohamed, Islam, Miller, Stacy, Schneiders, Famke, Laba, Joanna, Wilke, Derek, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Gaede, Stewart, Warner, Andrew, de Gruijl, Tanja D., Allan, Alison, and Palma, David A.
- Published
- 2020
- Full Text
- View/download PDF
3. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
- Author
-
Palma, David A., Olson, Robert, Harrow, Stephen, Correa, Rohann J. M., Schneiders, Famke, Haasbeek, Cornelis J. A., Rodrigues, George B., Lock, Michael, Yaremko, Brian P., Bauman, Glenn S., Ahmad, Belal, Schellenberg, Devin, Liu, Mitchell, Gaede, Stewart, Laba, Joanna, Mulroy, Liam, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Warner, Andrew, Slotman, Ben J., de Gruijl, Tanja D., Allan, Alison, and Senan, Suresh
- Published
- 2019
- Full Text
- View/download PDF
4. Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node
- Author
-
van Pul, Kim M., Vuylsteke, Ronald J.C.L.M., van de Ven, Rieneke, te Velde, Elisabeth A., Rutgers, Emiel J. Th., van den Tol, Petrousjka M., Stockmann, Hein B.A.C., and de Gruijl, Tanja D.
- Published
- 2019
- Full Text
- View/download PDF
5. Proteasome inhibitors as experimental therapeutics of autoimmune diseases.
- Author
-
Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, and Jansen, Gerrit
- Published
- 2015
- Full Text
- View/download PDF
6. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.
- Author
-
Turksma, Annelies W., Bontkes, Hetty J., Ruizendaal, Janneke J., Scholten, Kirsten B. J., Akershoek, Johanneke, Rampersad, Shakila, Moesbergen, Laura M., Cillessen, Saskia A. G. M., Santegoets, Saskia J. A. M., De Gruijl, Tanja D., René Leemans, C., Meijer, Chris J. L. M., and Hooijberg, Erik
- Subjects
DENDRITIC cells ,CANCER treatment ,CANCER patients ,LYMPHOCYTES ,MESSENGER RNA - Abstract
Background: New treatment modalities are needed for the treatment of cancers of the head and neck region (HNSCC). Survivin is important for the survival and proliferation of tumor cells and may therefore provide a target for immunotherapy. Here we focused on the ex vivo presence and in vitro induction of survivin specific T cells. Methods: Tetramer staining and ELIspot assays were used to document the presence of survivin specific T cells in patient derived material, and to monitor the presence and persistence of survivin specific T cells after repeated in vitro stimulation with autologous dendritic cells. Results: Ex vivo analysis showed the presence of survivin-specific T cells in the peripheral blood (by tetramer analysis) and in the draining lymph node (by ELIspot analysis) in a HNSCC and a locally advanced breast cancer patient respectively. However, we were unable to maintain isolated survivin specific T cells for prolonged periods of time. For the in vitro generation of survivin specific T cells, monocyte derived DC were electroporated with mRNA encoding full length survivin or a survivin mini-gene together with either IL21 or IL12 mRNA. Western blotting and immunohistochemical staining of dendritic cell cytospin preparations confirmed translation of the full length survivin protein. After repeated stimulation we observed an increase, followed by a decrease, of the number of survivin specific T cells. FACS sorted or limiting dilution cloned survivin specific T cells could not be maintained on feeder mix for prolonged periods of time. Protein expression analysis subsequently showed that activated, but not resting T cells contain survivin protein. Conclusions: Here we have shown that survivin specific T cells can be detected ex vivo in patient derived material. Furthermore, survivin specific T cells can be induced in vitro using autologous dendritic cells with enforced expression of survivin and cytokines. However, we were unable to maintain enriched or cloned survivin specific T cells for prolonged periods of time. Endogenous expression of survivin in activated T cells and subsequent fratricide killing might explain our in vitro observations. We therefore conclude that survivin, although it is a universal tumor antigen, might not be the ideal target for immunotherapeutic strategies for the treatment of cancer of the head and neck [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.
- Author
-
Santegoets, Saskia JAM, Turksma, Annelies W., Suhoski, Megan M., Stam, Anita G. M., Albelda, Steve M., Hooijberg, Erik, Scheper, Rik J., van den Eertwegh, Alfons J. M., Gerritsen, Winald R., Powell Jr., Daniel J., June, Carl H., and de Gruijl, Tanja D.
- Subjects
MELANOMA treatment ,T cells ,CYTOKINES ,LYMPHOCYTES ,INTERLEUKIN-21 ,CELL-mediated cytotoxicity - Abstract
Background: Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effector T cells requires extensive ex vivo expansion, often at the cost of T cell differentiation and potency. For the past 20 years, IL-2 has been the key cytokine applied in the expansion of TIL for ACT. However, the use of IL-2 has also led to collateral expansion of regulatory T cells (Tregs) and progressive T cell differentiation, factors known to limit in vivo persistence and activity of transferred TIL. The use of alternative T cell growth factors is therefore warranted. Here, we have compared the effects of IL-2, -15 and -21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma. Methods: We applied the K562-based artificial APC (aAPC) platform for the direct and rapid expansion of tumor infiltrating lymphocytes isolated from primary cancer specimens. These aAPC were engineered to express the Fc-γ receptor CD32 (for anti-CD3 antibody binding), the co-stimulatory molecule 4-1BBL, and to secrete either IL-2, IL-15 or IL-21 cytokine. Results: Although IL-2 aAPC induced the greatest overall TIL expansion, IL-21 aAPC induced superior expansion of CD8
+ T cells with a CD27+ CD28+ "young" phenotype and superior functional cytotoxic effector characteristics, without collateral expansion of Tregs. Conclusion: Our data rationalize the clinical application of IL-21-secreting aAPC as a standardized cell-based platform in the expansion of "young" effector TIL for ACT. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
8. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.
- Author
-
Santegoets, Saskia Jam, Turksma, Annelies W, Suhoski, Megan M, Stam, Anita Gm, Albelda, Steve M, Hooijberg, Erik, Scheper, Rik J, van den Eertwegh, Alfons Jm, Gerritsen, Winald R, Powell Jr, Daniel J, June, Carl H, de Gruijl, Tanja D, Santegoets, Saskia J A M, Stam, Anita G M, van den Eertwegh, Alfons J M, and Powell, Daniel J Jr
- Subjects
ANTIGENS ,BIOPSY ,CELL physiology ,CELL receptors ,CELLS ,CYTOKINES ,ENZYME-linked immunosorbent assay ,FLOW cytometry ,INTERLEUKINS ,LYMPHOCYTES ,RESEARCH funding ,T cells ,TUMORS ,PHENOTYPES - Abstract
Background: Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effector T cells requires extensive ex vivo expansion, often at the cost of T cell differentiation and potency. For the past 20 years, IL-2 has been the key cytokine applied in the expansion of TIL for ACT. However, the use of IL-2 has also led to collateral expansion of regulatory T cells (Tregs) and progressive T cell differentiation, factors known to limit in vivo persistence and activity of transferred TIL. The use of alternative T cell growth factors is therefore warranted. Here, we have compared the effects of IL-2, -15 and -21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma.Methods: We applied the K562-based artificial APC (aAPC) platform for the direct and rapid expansion of tumor infiltrating lymphocytes isolated from primary cancer specimens. These aAPC were engineered to express the Fc-γ receptor CD32 (for anti-CD3 antibody binding), the co-stimulatory molecule 4-1BBL, and to secrete either IL-2, IL-15 or IL-21 cytokine.Results: Although IL-2 aAPC induced the greatest overall TIL expansion, IL-21 aAPC induced superior expansion of CD8+ T cells with a CD27+ CD28+ "young" phenotype and superior functional cytotoxic effector characteristics, without collateral expansion of Tregs.Conclusion: Our data rationalize the clinical application of IL-21-secreting aAPC as a standardized cell-based platform in the expansion of "young" effector TIL for ACT. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
9. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
- Author
-
Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, and Jansen G
- Abstract
Background: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence., Methods: Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC)., Results: Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10-12 fold resistance to BTZ associated with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2-4 fold increase in the mRNA and protein levels of the constitutive β5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914. Finally, in association with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC., Conclusions: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.
- Published
- 2013
- Full Text
- View/download PDF
10. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
- Author
-
Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, and van der Vliet HJ
- Subjects
- Administration, Oral, Carcinoma, Renal Cell immunology, Disease Progression, Dose-Response Relationship, Drug, Drug Therapy, Combination methods, Everolimus, Female, Humans, Kidney Neoplasms immunology, Male, Netherlands, Sirolimus therapeutic use, Survival Analysis, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory immunology, Antineoplastic Agents, Alkylating administration & dosage, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell secondary, Cyclophosphamide administration & dosage, Immunosuppressive Agents therapeutic use, Kidney Neoplasms drug therapy, Sirolimus analogs & derivatives, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Background: For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survival. Intriguingly, inhibition of mTOR also promotes expansion of immunosuppressive regulatory T cells (Tregs) that can inhibit anti-tumor immune responses in a clinically relevant way in various tumor types including RCC. This study intends to investigate whether the antitumor efficacy of everolimus can be increased by preventing the detrimental everolimus induced expansion of Tregs using a metronomic schedule of cyclophosphamide., Methods/design: This phase I-II trial is a national multi-center study of different doses and schedules of low-dose oral cyclophosphamide in combination with a fixed dose of everolimus in patients with mRCC not amenable to or progressive after a VEGF-receptor tyrosine kinase inhibitor containing treatment regimen. In the phase I part of the study the optimal Treg-depleting dose and schedule of metronomic oral cyclophosphamide when given in combination with everolimus will be determined. In the phase II part of the study we will evaluate whether the percentage of patients progression free at 4 months of everolimus treatment can be increased from 50% to 70% by adding metronomic cyclophosphamide (in the dose and schedule determined in the phase I part). In addition to efficacy, we will perform extensive immune monitoring with a focus on the number, phenotype and function of Tregs, evaluate the safety and feasibility of the combination of everolimus and cyclophosphamide, perform monitoring of selected angiogenesis parameters and analyze everolimus and cyclophosphamide drug levels., Discussion: This phase I-II study is designed to determine whether metronomic cyclophosphamide can be used to counter the mTOR inhibitor everolimus induced Treg expansion in patients with metastatic renal cell carcinoma and increase the antitumor efficacy of everolimus., Trial Registration: ClinicalTrials.gov Identifier NCT01462214, EudraCT number 2010-024515-13, Netherlands Trial Register number NTR3085.
- Published
- 2011
- Full Text
- View/download PDF
11. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.
- Author
-
van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, and Giaccone G
- Subjects
- Dendritic Cells pathology, Female, G(M3) Ganglioside immunology, Humans, Immunohistochemistry, Male, Microvessels immunology, Microvessels pathology, Middle Aged, Neovascularization, Pathologic immunology, Neovascularization, Pathologic pathology, STAT3 Transcription Factor immunology, Tissue Array Analysis, Carcinoma, Non-Small-Cell Lung blood supply, Carcinoma, Non-Small-Cell Lung immunology, Dendritic Cells immunology, G(M3) Ganglioside biosynthesis, Lung Neoplasms blood supply, Lung Neoplasms immunology, STAT3 Transcription Factor biosynthesis
- Abstract
Background: Tumor immune escape and angiogenesis contribute to tumor progression, and gangliosides and activation of signal transducer and activator of transcription (STAT)-3 are implicated in these processes. As both are considered as novel therapeutic targets, we assessed the possible association of ganglioside GM3 expression and STAT3 activation with suppression of dendritic cell (DC) activation and angiogenesis in non-small cell lung cancer (NSCLC)., Methods: Immunohistochemistry was performed on a tissue array to determine N-glycolyl GM3 (GM3) and phosphorylated STAT3 (pSTAT3) expression in 176 primary NSCLC resections. Median values of GM3 and pSTAT3 expression were used as cut off. Microvessel density (MVD) was determined by CD34 staining and morphology. CD1a and CD83 were used to determine infiltrating immature and mature dendritic cells, respectively., Results: 94% and 71% of the NSCLC samples expressed GM3 and nuclear pSTAT3, respectively. Median overall survival was 40.0 months. Both low GM3 expression and high pSTAT3 expression were associated with a worse survival, which reached near significance for GM3 (P = 0.08). Microvessel density (MVD), determined by CD34 staining and morphology, was lower in NSCLC samples with high GM3 expression. CD1a+ cells (immature DCs) were more frequent in NSCLC tissues as compared to peritumoral lung tissue, while CD83+ cells (mature DCs) were more frequent in peritumoral lung tissue. CD83+ DCs were less frequent in NSCLC tissues with high GM3 expression., Conclusion: GM3 and pSTAT3 are widely expressed in NSCLC. Based on CD83 expression, GM3, but not pSTAT3, appeared to be involved in tumor-induced DC suppression. pSTAT3 expression was not associated with MVD, while GM3 might play an anti-angiogenic role.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.